Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapies.

Bui TBV, Wolf DM, Bruck MC, Moore K, Lien J, Choi SDW, Warhadpande S, Parizadeh A, Dillon D, Overmoyer B, Lynce F, I-SPY 2 Investigators, Nijman IJ, Burgering BMT, Harris IS, Esserman LJ, Veer LJV', Rosenbluth JM